The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation
JG Andrade, M Aguilar, C Atzema, A Bell… - Canadian Journal of …, 2020 - Elsevier
Abstract The Canadian Cardiovascular Society (CCS) atrial fibrillation (AF) guidelines
program was developed to aid clinicians in the management of these complex patients, as …
program was developed to aid clinicians in the management of these complex patients, as …
[HTML][HTML] Rivaroxaban in rheumatic heart disease–associated atrial fibrillation
SJ Connolly, G Karthikeyan, M Ntsekhe… - … England Journal of …, 2022 - Mass Medical Soc
Abstract Background Testing of factor Xa inhibitors for the prevention of cardiovascular
events in patients with rheumatic heart disease–associated atrial fibrillation has been …
events in patients with rheumatic heart disease–associated atrial fibrillation has been …
Diagnosis and treatment of acute coronary syndromes: a review
DL Bhatt, RD Lopes, RA Harrington - Jama, 2022 - jamanetwork.com
Importance Acute coronary syndromes (ACS) are characterized by a sudden reduction in
blood supply to the heart and include ST-segment elevation myocardial infarction (STEMI) …
blood supply to the heart and include ST-segment elevation myocardial infarction (STEMI) …
Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment
Intracranial atherosclerotic stenosis (ICAS) is one of the most frequent causes of stroke
worldwide and confers one of the greatest risks of recurrent stroke compared with other …
worldwide and confers one of the greatest risks of recurrent stroke compared with other …
[HTML][HTML] Colchicine in patients with chronic coronary disease
SM Nidorf, ATL Fiolet, A Mosterd… - New England journal …, 2020 - Mass Medical Soc
Background Evidence from a recent trial has shown that the antiinflammatory effects of
colchicine reduce the risk of cardiovascular events in patients with recent myocardial …
colchicine reduce the risk of cardiovascular events in patients with recent myocardial …
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes …
F Cosentino, PJ Grant, V Aboyans… - European heart …, 2020 - academic.oup.com
Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …
exercising their clinical judgment, as well as in the determination and the implementation of …
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary …
Health professionals are encouraged to take the ESC Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …
exercising their clinical judgment, as well as in the determination and the implementation of …
Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo …
A Shoamanesh, H Mundl, EE Smith, J Masjuan… - The Lancet, 2022 - thelancet.com
Summary Background Asundexian (Bayer AG, Leverkusen, Germany), an oral small
molecule factor XIa (FXIa) inhibitor, might prevent thrombosis without increasing bleeding …
molecule factor XIa (FXIa) inhibitor, might prevent thrombosis without increasing bleeding …
[HTML][HTML] Rivaroxaban in peripheral artery disease after revascularization
Background Patients with peripheral artery disease who have undergone lower-extremity
revascularization are at high risk for major adverse limb and cardiovascular events. The …
revascularization are at high risk for major adverse limb and cardiovascular events. The …
Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research
B Bikdeli, MV Madhavan, A Gupta… - Thrombosis and …, 2020 - thieme-connect.com
Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness
caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The …
caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The …